Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gocatamig and Durvalumab in Limited-Stage Small Cell Lung Cancer
NCT07908537Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2026
- Primary completion
- Dec 2031
01
Overview
A Phase 3 trial of gocatamig in small cell lung cancer (SCLC), sponsored by Merck & Co.. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
gocatamig
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07908537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07908537.